Genocea is harnessing the power of T cell immunity to develop the next generation of vaccines. Using our proprietary ATLAS™ platform, we identify and deploy T cell antigens to target large and complex pathogens that traditional discovery approaches cannot address sufficiently, including HSV-2, Pneumococcus, Chlamydia and malaria.
Technology > More
